Shenzhen Zhongke Aishen Pharmaceutical

Shenzhen Zhongke Aishen Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Shenzhen, China, specializing in the development of innovative small molecule therapeutics. Founded in 2016, the company focuses on high-impact targets within oncology and metabolic disorders, utilizing a structure-based drug design approach. Its lead program, AS-003, is a highly selective URAT1 inhibitor currently undergoing Phase 2 clinical evaluation for the treatment of gout and hyperuricemia. The company's oncology portfolio includes AS-1702, a CDK4/6 inhibitor in early clinical development, and several preclinical candidates targeting FGFR and other kinases. Zhongke Aishen maintains strong ties with the Shenzhen Institute of Advanced Technology to drive its research and development efforts.